[go: up one dir, main page]

UY30905A1 - Composiciones para mejorar la absorcion gastrointestinal de nutrientes y farmacos - Google Patents

Composiciones para mejorar la absorcion gastrointestinal de nutrientes y farmacos

Info

Publication number
UY30905A1
UY30905A1 UY30905A UY30905A UY30905A1 UY 30905 A1 UY30905 A1 UY 30905A1 UY 30905 A UY30905 A UY 30905A UY 30905 A UY30905 A UY 30905A UY 30905 A1 UY30905 A1 UY 30905A1
Authority
UY
Uruguay
Prior art keywords
nutrients
compositions
pharmacos
gastrointestinal absorption
improve gastrointestinal
Prior art date
Application number
UY30905A
Other languages
English (en)
Inventor
Saul Levinson
Jonathan David Bortz
Marc Hermelin
Original Assignee
Drugtech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drugtech Corp filed Critical Drugtech Corp
Publication of UY30905A1 publication Critical patent/UY30905A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion proporciona composiciones farmaceuticas y metodos para mejorar la absorcion de nutrientes y/o farmacos en el tracto gastrointestinal de un sujeto. Las composiciones contienen un primer agente que aumenta el PH del estomago y uno o mas agentes seleccionados entre un agente reductor del PH, una vitamina, un mineral y un farmaco.
UY30905A 2007-02-09 2008-02-08 Composiciones para mejorar la absorcion gastrointestinal de nutrientes y farmacos UY30905A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88904707P 2007-02-09 2007-02-09

Publications (1)

Publication Number Publication Date
UY30905A1 true UY30905A1 (es) 2008-09-02

Family

ID=39686026

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30905A UY30905A1 (es) 2007-02-09 2008-02-08 Composiciones para mejorar la absorcion gastrointestinal de nutrientes y farmacos

Country Status (7)

Country Link
US (1) US20080193531A1 (es)
AR (1) AR065246A1 (es)
CL (1) CL2008000411A1 (es)
PE (1) PE20090038A1 (es)
TW (1) TW200843802A (es)
UY (1) UY30905A1 (es)
WO (1) WO2008100767A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104383542B (zh) 2003-04-08 2017-09-26 普罗热尼奇制药公司 包含甲基纳曲酮的药物配方
IL169678A (en) 2005-07-14 2010-11-30 Innova Sa Sweetener compositions
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
ITMI20071979A1 (it) * 2007-10-12 2009-04-13 Massimo Baldacci Formulazioni farmaceutiche contenenti ferro bisglicinato chelato
GB0808835D0 (en) * 2008-05-15 2008-06-18 Vitra Pharmaceuticals Ltd Therapeutic compositions
EP2264024A1 (en) 2008-10-14 2010-12-22 LEK Pharmaceuticals d.d. Process for the preparation of enantiomerically enriched proton pump inhibitors
US8859003B2 (en) * 2009-06-05 2014-10-14 Intercontinental Great Brands Llc Preparation of an enteric release system
US20100310726A1 (en) * 2009-06-05 2010-12-09 Kraft Foods Global Brands Llc Novel Preparation of an Enteric Release System
US20100307542A1 (en) * 2009-06-05 2010-12-09 Kraft Foods Global Brands Llc Method of Reducing Surface Oil on Encapsulated Material
US9968564B2 (en) * 2009-06-05 2018-05-15 Intercontinental Great Brands Llc Delivery of functional compounds
KR20120046753A (ko) 2009-07-21 2012-05-10 케릭스 바이오파마슈티컬스 인코포레이티드 구연산철 투여형태
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
HRP20171755T1 (hr) 2009-07-31 2017-12-29 Grünenthal GmbH Postupak kristalizacije i biološka raspoloživost
NZ703564A (en) 2010-03-11 2016-08-26 Wyeth Llc Oral formulations and lipophilic salts of methylnaltrexone
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
US9433583B2 (en) 2011-04-22 2016-09-06 Frank J. Farrell Colon vitamin
LT2659881T (lt) * 2012-04-30 2018-02-12 Tillotts Pharma Ag Uždelsto atpalaidavimo vaisto forma
RU2493845C1 (ru) * 2012-06-07 2013-09-27 Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" Композиция для лечения рассеянного склероза (варианты)
FR2992219B1 (fr) * 2012-06-22 2014-07-11 Aditec Lab Composition pour le traitement de l'hypocalcemie chez les ruminants
US8859005B2 (en) 2012-12-03 2014-10-14 Intercontinental Great Brands Llc Enteric delivery of functional ingredients suitable for hot comestible applications
PL2967117T3 (pl) * 2013-03-14 2020-11-30 Albion Laboratories, Inc. Kompozycja odżywcza oszczędzająca fosfor
CA2913413C (en) * 2013-06-06 2021-11-23 Amip, Llc Iron supplement
BR112016004863B1 (pt) 2013-10-29 2022-09-20 Tillotts Pharma Ag Formulação de droga de liberação retardada
US10034899B2 (en) 2013-11-27 2018-07-31 BioPharmX, Inc. Solid oral dosage form for breast symptoms
US20160242439A1 (en) 2014-04-04 2016-08-25 Douxmatok Ltd Method for producing sweetener compositions and sweetener compositions
US10231476B2 (en) 2014-04-04 2019-03-19 Douxmatok Ltd Sweetener compositions and foods, beverages, and consumable products made thereof
US10207004B2 (en) * 2014-04-04 2019-02-19 Douxmatok Ltd Method for producing sweetener compositions and sweetener compositions
WO2015175479A1 (en) * 2014-05-13 2015-11-19 Steven Baranowitz Pharmaceutical composition
US20160339086A1 (en) * 2015-05-19 2016-11-24 Suzy Cohen Compositions and methods for treating thyroid disease
CN107666910A (zh) * 2015-05-29 2018-02-06 强生消费者公司 具有高抗微生物能力的有机柑橘类提取物和木糖醇作为液体、乳液、悬浮液、霜膏和抗酸剂中的防腐剂体系的用途
US10674746B2 (en) 2015-10-27 2020-06-09 Cytozyme Animal Nutrition, Inc. Animal nutrition compositions and related methods
WO2017075289A1 (en) 2015-10-27 2017-05-04 Cytozyme Animal Nutrition, Inc. Animal nutrition compositions and related methods
US10702590B2 (en) 2016-04-12 2020-07-07 Script Essentials, Llc Compositions and methods for treating thyroid disease
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
EP3496714A4 (en) 2016-08-11 2020-04-22 Adamis Pharmaceuticals Corporation DRUG COMPOSITIONS.
US9974804B1 (en) * 2017-09-08 2018-05-22 David Lloyd Smith Strontium-based composition, product, and method of using the same to control progression of osteoarthritis osteoporosis and tooth decay
US11564910B2 (en) 2017-12-08 2023-01-31 Adamis Pharmaceuticals Corporation Drug compositions
CN108498868B (zh) * 2018-04-03 2020-09-15 北京大学口腔医学院 具有细胞外基质电学拓扑特征的带电复合膜及其制备方法
US20210093549A1 (en) 2019-09-30 2021-04-01 The Procter & Gamble Company Fluoride-Free Anticavity Oral Care Compositions
US20220304919A1 (en) * 2021-03-25 2022-09-29 The Procter & Gamble Company Edible Oral Compositions Comprising Hops
CN113491302A (zh) * 2021-07-09 2021-10-12 北京东方天合生物技术有限责任公司 一种预防奶牛酮病的过瘤胃烟酸添加剂及其制备方法
WO2024039593A1 (en) * 2022-08-15 2024-02-22 Biolink Life Sciences, Inc. Calcium succinate monohydrate formulation
CN115463124B (zh) * 2022-11-02 2024-04-05 海而思（郑州）科技有限公司 一种补铁泡腾片及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3076747A (en) * 1960-02-03 1963-02-05 Haessle Ab Pharmaceutical iron preparations
JPS57156419A (en) * 1981-03-24 1982-09-27 Kyowa Chem Ind Co Ltd Remedy for sideropenia
US5229131A (en) * 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
US6251883B1 (en) * 1991-01-08 2001-06-26 Bone Care International, Inc. Methods for preparation and use of 1α,24(S)-dihydroxy vitamin D2
DE69713948D1 (de) * 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
US7089934B2 (en) * 2000-02-28 2006-08-15 Vectura Limited Delivery of oral drugs
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
EP1763337A2 (en) * 2003-12-31 2007-03-21 Actavis Group HF Immediate, controlled and sustained release formulations of galanthamine
US20050282756A1 (en) * 2004-06-18 2005-12-22 Mehta Nozer M Oral delivery of peptide pharmaceutical compositions
US20060280795A1 (en) * 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system

Also Published As

Publication number Publication date
WO2008100767A1 (en) 2008-08-21
TW200843802A (en) 2008-11-16
AR065246A1 (es) 2009-05-27
US20080193531A1 (en) 2008-08-14
CL2008000411A1 (es) 2008-08-08
PE20090038A1 (es) 2009-01-30

Similar Documents

Publication Publication Date Title
UY30905A1 (es) Composiciones para mejorar la absorcion gastrointestinal de nutrientes y farmacos
CL2008001124A1 (es) Formulacion farmaceutica que comprende al menos un derivado de acido lipoico y un reactivo formador de par ionico, util en el tratamiento del cancer.
MX2013003282A (es) Materiales y metodos para mejorar la funcion gastrointestinal.
HN2010002518A (es) Composicion farmaceutica que comprende una sal de estroncio, vitamina d y una ciclodextrina
CL2007003341A1 (es) Compuestos derivados de imidazotriazinas; composicion farmaceutica, util para el tratamiento del cancer, arteroesclerosis y enfermedades cardiovasculares entre otras.
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
CR20110599A (es) Composiciones farmacéuticamente activas que comprenden moduladores de estrés oxidativo (osm), nuevas entidades químicas, composiciones y usos
UY31673A1 (es) "derivados heterocíclicos de urea y métodos de uso de los mismos-211"
CL2011003350A1 (es) Compuestos derivados de heterociclo nitrogenados, moduladores pkm2; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
GT200900027A (es) Compuestos organicos
UY36075A (es) Derivados de tubulisina
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
DOP2007000043A (es) Derivados de cromanol sustituidos y su uso
BR112012016543A2 (pt) Tratamento com vb-201
EA201001288A1 (ru) Лечение гипертонии 25-гидроксивитамином d3
CL2009000727A1 (es) Compuestos derivados de n-hidroxi-3-fenilprop-2-enemida y n-hidroxi-3-fenilpropanamida sustituidos; inhibidores de la enzima desacetilasa; su composicion farmaceutica; utiles en el tratamiento del cancer, tumores, psoriasis, alzheimer, entre otras.
UY29395A1 (es) Formulación de medicamentos conteniendo vardenafilo.
UY32735A (es) Formulaciones de imiquimod de concentración de dosificación inferior y regímenes de dosificación cortos para tratar verrugas genitales y perianales.
AR070392A1 (es) Composiciones de tabletas de ranitidina de desintegracion oral y sus metodos de eleboracion
GT200800235A (es) Formulacion de medicamento liquida
GT201300058A (es) Composiciones de anticuerpos anti-vegfr-3
DOP2006000208A (es) Suplementos nutricionales con fitosterol
CO6450623A2 (es) Parasiticidas sanguineos
AR076576A1 (es) Procedimiento para estabilizar un suplemento dietetico para facilitar la salud de las articulaciones en seres humanos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170919